2 Results Found

Advanced Search

Select all

Results per page

Select all

Review

33 Pages

Integrated Stress Response (ISR) Modulators in Vascular Diseases

Alexander Kalinin,
Ekaterina Zubkova,
Irina Beloglazova,
Yelena Parfyonova and
Mikhail Menshikov

Cells2026, 15(1), 2;https://doi.org/10.3390/cells15010002

-

19 December 2025

Vascular dysfunction lies at the core of cardiovascular diseases—the leading cause of global morbidity and mortality. Despite their prevalence, therapeutic options remain limited, in part due to an incomplete understanding of the molecular mech...

Full Article

Article

44 Citations

11,890 Views

13 Pages

MEK Inhibition in a Newborn with RAF1-Associated Noonan Syndrome Ameliorates Hypertrophic Cardiomyopathy but Is Insufficient to Revert Pulmonary Vascular Disease

Alessandro Mussa,
Diana Carli,
Elisa Giorgio,
Anna Maria Villar,
Simona Cardaropoli,
Caterina Carbonara,
Maria Francesca Campagnoli,
Paolo Galletto,
Martina Palumbo and
Simone Olivieri
+ 7 authors

Genes2022, 13(1), 6;https://doi.org/10.3390/genes13010006

-

21 December 2021

The RAF1:p.Ser257Leu variant is associated with severe Noonan syndrome (NS), progressive hypertrophic cardiomyopathy (HCM), and pulmonary hypertension. Trametinib, a MEK-inhibitor approved for treatment of RAS/MAPK-mutated cancers, is an emerging tre...

Full Article